amlodipine/valsartan novartis 10/160 amlodipine 10 mg/valsartan 160 mg film-coated tablet blister pack
novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; crospovidone; titanium dioxide; hypromellose; purified talc; macrogol 4000; iron oxide red; iron oxide yellow - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.
amlodipine/valsartan novartis 5/160 amlodipine 5 mg/valsartan 160 mg film-coated tablets blister pack
novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; hypromellose; purified talc; iron oxide yellow; macrogol 4000; titanium dioxide - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.
novartis prepandemic influenza vaccine (h5n1) suspension for injection 0.5ml in pre-filled syringe
novartis (singapore) pte ltd - influenza virus surface antigens (haemagglutinin and neuraminidase) a/vietnam/1194/2004 (h5n1) - like strain used (nibrg-14) - injection, suspension - >or= 7.5 ug ha
prexige
novartis new zealand ltd - lumiracoxib 100mg (release testing to occur at novartis ag, lichstrasse, basel.) - film coated tablet - 100 mg - active: lumiracoxib 100mg (release testing to occur at novartis ag, lichstrasse, basel.) excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry opadry white 00f18296 povidone titanium dioxide
prexige
novartis new zealand ltd - lumiracoxib 200mg (release testing to occur at novartis ag, lichstrasse, basel.) - film coated tablet - 200 mg - active: lumiracoxib 200mg (release testing to occur at novartis ag, lichstrasse, basel.) excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry black 00f17713 opadry red 00f15613 opadry white 00f18296 povidone titanium dioxide
prexige
novartis new zealand ltd - lumiracoxib 400mg (release testing to occur at novartis ag, lichstrasse, basel.) - film coated tablet - 400 mg - active: lumiracoxib 400mg (release testing to occur at novartis ag, lichstrasse, basel.) excipient: croscarmellose sodium 00f17713 basic coating premix black magnesium stearate microcrystalline cellulose opadry opadry white 00f18296 povidone
novartis octreotide lar octreotide (as acetate) 30 mg modified release injection vial plus diluent prefilled syringe composite p
novartis pharmaceuticals australia pty ltd - octreotide -
novartis octreotide lar octreotide (as acetate) 20 mg modified release injection vial plus diluent prefilled syringe composite p
novartis pharmaceuticals australia pty ltd - octreotide -
novartis octreotide lar octreotide (as acetate) 10 mg modified release injection vial plus diluent prefilled syringe composite p
novartis pharmaceuticals australia pty ltd - octreotide -
fluorescein novartis
novartis pharmaceuticals australia pty ltd - fluorescein sodium -